Literature DB >> 33211240

Unrecognized pulmonary arterial hypertension in hospitalized patients.

Andres Mora Carpio1, Aaron Goertz1, Colleen Kelly2, Leslee Willes2, Stuart F Quan3,4, Gregg S Pressman1, Abesh Niroula5, Sunil Sharma6.   

Abstract

Pulmonary hypertension (PH) is an underdiagnosed and potentially fatal condition. The utility of screening for PH in hospitalized patients undergoing echocardiography is unknown. The goal of this study was to determine the prevalence of undiagnosed pulmonary hypertension (PH) and probable pulmonary arterial hypertension (PAH) in hospitalized patients undergoing echocardiography for any indication. All hospitalized patients undergoing echocardiography were identified and echocardiographs reviewed prospectively for the presence of a tricuspid regurgitant (TR) jet. Electronic medical records (EMR) of patients with a TR jet ≥ 3 m/s were reviewed for identifiable causes of pulmonary hypertension. Patients with no identifiable cause were classified as presumptive World Health Organization (WHO) Group 1 PH (also known as PAH). These PAH patients were compared to other PH patients for baseline demographic characteristics and comorbidities as well as 30-day readmission and mortality. The admitting physicians of patients classified as PH were advised to consider further evaluation including right heart catheterization. We reviewed 4417 consecutive echocardiograms and identified 448 with a TR jet ≥ 3 m/s. Of these 448 patients with PH, 47 were identified as "presumptive PAH" and the other 401 as having PH belonging to WHO Groups 2-5. Presumptive PAH represented 1% of screened echocardiograms and 10.5% of those identified to have an elevated TR jet. Of the patients identified as presumptive PAH, 8 underwent further evaluation including a right heart catheterization, where 5 were confirmed to have PAH. Kaplan-Meier analysis revealed 30-day readmission was higher among those classified as PAH. Our data shows that pulmonary hypertension, as defined by TR jet ≥ 3 m/s, is frequently encountered in hospitalized patients undergoing echocardiography for any reason. A careful review of echocardiogram findings and clinical history suggested 10.5% of those with PH (and 1% of all screened patients) may meet the criteria for PAH. Considering PH is a fatal condition which is frequently missed, a hospital screening program seems feasible.

Entities:  

Keywords:  Echocardiography; Hospitalized patients; Pulmonary hypertension

Year:  2020        PMID: 33211240     DOI: 10.1007/s10554-020-02108-9

Source DB:  PubMed          Journal:  Int J Cardiovasc Imaging        ISSN: 1569-5794            Impact factor:   2.357


  10 in total

Review 1.  Screening for pulmonary arterial hypertension in systemic sclerosis.

Authors:  J-L Vachiéry; G Coghlan
Journal:  Eur Respir Rev       Date:  2009-09

Review 2.  Updated clinical classification of pulmonary hypertension.

Authors:  Gerald Simonneau; Michael A Gatzoulis; Ian Adatia; David Celermajer; Chris Denton; Ardeschir Ghofrani; Miguel Angel Gomez Sanchez; R Krishna Kumar; Michael Landzberg; Roberto F Machado; Horst Olschewski; Ivan M Robbins; Rogiero Souza
Journal:  J Am Coll Cardiol       Date:  2013-12-24       Impact factor: 24.094

Review 3.  Pulmonary hypertension: diagnosis, imaging techniques, and novel therapies.

Authors:  Alan B Goldberg; Wojciech Mazur; Dinesh K Kalra
Journal:  Cardiovasc Diagn Ther       Date:  2017-08

4.  Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival.

Authors:  Marc Humbert; Azzedine Yaici; Pascal de Groote; David Montani; Olivier Sitbon; David Launay; Virginie Gressin; Loïc Guillevin; Pierre Clerson; Gérald Simonneau; Eric Hachulla
Journal:  Arthritis Rheum       Date:  2011-11

5.  Screening for pulmonary arterial hypertension in an unselected prospective systemic sclerosis cohort.

Authors:  Els Vandecasteele; Benny Drieghe; Karin Melsens; Kristof Thevissen; Michel De Pauw; Ellen Deschepper; Saskia Decuman; Carolien Bonroy; Yves Piette; Filip De Keyser; Guy Brusselle; Vanessa Smith
Journal:  Eur Respir J       Date:  2017-05-11       Impact factor: 16.671

Review 6.  Echocardiographic indexes for the non-invasive evaluation of pulmonary hemodynamics.

Authors:  Alberto Milan; Corrado Magnino; Franco Veglio
Journal:  J Am Soc Echocardiogr       Date:  2010-03       Impact factor: 5.251

7.  Delay in recognition of pulmonary arterial hypertension: factors identified from the REVEAL Registry.

Authors:  Lynette M Brown; Hubert Chen; Scott Halpern; Darren Taichman; Michael D McGoon; Harrison W Farber; Adaani E Frost; Theodore G Liou; Michelle Turner; Kathy Feldkircher; Dave P Miller; C Gregory Elliott
Journal:  Chest       Date:  2011-03-10       Impact factor: 9.410

8.  2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT).

Authors:  Nazzareno Galiè; Marc Humbert; Jean-Luc Vachiery; Simon Gibbs; Irene Lang; Adam Torbicki; Gérald Simonneau; Andrew Peacock; Anton Vonk Noordegraaf; Maurice Beghetti; Ardeschir Ghofrani; Miguel Angel Gomez Sanchez; Georg Hansmann; Walter Klepetko; Patrizio Lancellotti; Marco Matucci; Theresa McDonagh; Luc A Pierard; Pedro T Trindade; Maurizio Zompatori; Marius Hoeper
Journal:  Eur Heart J       Date:  2015-08-29       Impact factor: 29.983

9.  Overview of current therapeutic approaches for pulmonary hypertension.

Authors:  Jason A Stamm; Michael G Risbano; Michael A Mathier
Journal:  Pulm Circ       Date:  2011 Apr-Jun       Impact factor: 3.017

10.  Prognostic Effect and Longitudinal Hemodynamic Assessment of Borderline Pulmonary Hypertension.

Authors:  Tufik R Assad; Bradley A Maron; Ivan M Robbins; Meng Xu; Shi Huang; Frank E Harrell; Eric H Farber-Eger; Quinn S Wells; Gaurav Choudhary; Anna R Hemnes; Evan L Brittain
Journal:  JAMA Cardiol       Date:  2017-12-01       Impact factor: 14.676

  10 in total
  1 in total

1.  The Main Pulmonary Artery to the Ascending Aorta Diameter Ratio (PA/A) as a Predictor of Worse Outcomes in Hospitalized Patients with AECOPD.

Authors:  Yusheng Cheng; Lingling Li; Xiongwen Tu; Renguang Pei
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2022-05-16
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.